Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
MeSH Number(s)
E02.183.750.500
E02.319.077.500
E02.319.310.037
Concept/Terms
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 42 | 17 | 59 |
1995 | 39 | 17 | 56 |
1996 | 55 | 23 | 78 |
1997 | 56 | 17 | 73 |
1998 | 70 | 23 | 93 |
1999 | 58 | 32 | 90 |
2000 | 61 | 26 | 87 |
2001 | 59 | 22 | 81 |
2002 | 68 | 32 | 100 |
2003 | 75 | 40 | 115 |
2004 | 85 | 39 | 124 |
2005 | 103 | 40 | 143 |
2006 | 109 | 54 | 163 |
2007 | 97 | 49 | 146 |
2008 | 111 | 60 | 171 |
2009 | 136 | 55 | 191 |
2010 | 149 | 52 | 201 |
2011 | 144 | 71 | 215 |
2012 | 161 | 59 | 220 |
2013 | 163 | 70 | 233 |
2014 | 197 | 100 | 297 |
2015 | 203 | 83 | 286 |
2016 | 174 | 94 | 268 |
2017 | 182 | 103 | 285 |
2018 | 234 | 78 | 312 |
2019 | 271 | 93 | 364 |
2020 | 224 | 131 | 355 |
2021 | 185 | 159 | 344 |
2022 | 45 | 231 | 276 |
2023 | 9 | 220 | 229 |
2024 | 0 | 21 | 21 |
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer. Anticancer Res. 2024 Mar; 44(3):1219-1226.
-
ASO Visual Abstract: Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin. Ann Surg Oncol. 2024 03; 31(3):2021.
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 2024 Mar 01; 109(3):867-876.
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 2024 Mar 01; 109(3):895-905.
-
Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy. Biomacromolecules. 2024 Mar 11; 25(3):1800-1809.
-
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2024 Feb 16; 30(4):754-766.
-
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin Cancer Res. 2024 Feb 16; 30(4):767-778.
-
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. Clin Cancer Res. 2024 Feb 16; 30(4):793-802.
-
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3ß Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clin Cancer Res. 2024 Feb 01; 30(3):522-531.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.